Lutetium-DOTATATE for relapsed or hard-to-treat neuroblastoma in children
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests a targeted radioactive medicine called 177Lutetium-DOTATATE in children with high-risk neuroblastoma that has returned or did not respond to treatment. It’s designed for tumors that show strong uptake on special scans, which may help the medicine find and treat cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has confirmed neuroblastoma on biopsy/pathology
- Tumor scans show the tumor lights up on 68Ga-DOTATATE PET/CT more than the liver (within 2 months)
- Your child is over 18 months old, and expected to live more than 3 months
- Your child must be well enough for treatment (Lansky score >50 if age ≤12, or Karnofsky >50 if age >12)
- Must be well recovered from prior treatments and surgery, with a washout period of about 2 weeks
- Recent blood/organ tests must be within required ranges, including enough white cells, platelets, and kidney function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well a new PET/CT scan using 68Ga-DOTATATE can find neuroblastoma. It’s for children and young adults who are being planned for a different scan (123I-MIBG) to compare imaging results.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests a radioactive drug called Lutathera for people with neuroendocrine tumors that are not in the stomach or intestines and can't be removed by surgery. The drug targets a specific receptor on the tumor cells to deliver radiation directly, which may help slow or shrink the cancer.
This Phase 2 trial tests whether 177Lu-DOTATATE can slow or shrink stage IV or recurrent breast cancer. It targets tumor “receptors” found on scans, using a radioactive medicine that delivers radiation directly to cancer cells.
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
Hear when a new Neuroblastoma Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.